Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company ...
LONDON — Roche executives on Monday argued that their experimental obesity medications would prove to have advantages over their rivals’ ...
Repare Therapeutics has three cancer drug candidates in the clinic and another one expected to enter Phase 1 by the ...
Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in patients with a neurological condition ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.